Skip to main content

Jones James's Form 4 filing

Cumberland Pharmaceuticals Inc (CPIX) · filed Dec 30, 2024

Accession no.
0001628280-24-052608
Filed
Dec 30, 2024
Trade date
Dec 2-20, 2024
Filing delay
28 daysLate
Rule 10b5-1 plan
Checked

This filing lists 15 non-derivative transactions and 0 derivative transactions. Open-market purchases total $1.32K. It was filed 28 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Jones JamesCIK 0001490829Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 2, 2024Common StockPPurchaseAcquired+70$1.33+$93.139,447Direct
Dec 3, 2024Common StockPPurchaseAcquired+70$1.26+$88.239,517Direct
Dec 4, 2024Common StockPPurchaseAcquired+70$1.22+$85.439,587Direct
Dec 5, 2024Common StockPPurchaseAcquired+65$1.20+$7839,652Direct
Dec 6, 2024Common StockPPurchaseAcquired+70$1.20+$8439,722Direct
Dec 9, 2024Common StockPPurchaseAcquired+70$1.25+$87.539,792Direct
Dec 10, 2024Common StockPPurchaseAcquired+32$2.48+$79.3639,824Direct
Dec 11, 2024Common StockPPurchaseAcquired+32$2.29+$73.2839,856Direct
Dec 12, 2024Common StockPPurchaseAcquired+32$2.19+$70.0839,888Direct
Dec 13, 2024Common StockPPurchaseAcquired+32$2.33+$74.5639,920Direct
Dec 16, 2024Common StockPPurchaseAcquired+49$2.21+$108.2939,969Direct
Dec 17, 2024Common StockPPurchaseAcquired+49$2.12+$103.8840,018Direct
Dec 18, 2024Common StockPPurchaseAcquired+49$2.19+$107.3140,067Direct
Dec 19, 2024Common StockPPurchaseAcquired+40$2.33+$93.240,107Direct
Dec 20, 2024Common StockPPurchaseAcquired+39$2.35+$91.6540,146Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)